New drug cocktail aims to outsmart aggressive myeloma

NCT ID NCT07029776

Not yet recruiting Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving two bispecific antibodies (teclistamab and talquetamab) in sequence, along with other drugs, can improve survival in 50 people with high-risk multiple myeloma. Some participants may also receive a stem cell transplant if cancer cells remain after initial treatment. The goal is to achieve a complete response and keep the cancer from progressing for at least two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teclistamab, talquetamab, daratumumab, lenalidomide, and melphalan-based stem cell transplant
What this could lead to: If successful, this approach could offer a new treatment sequence that improves survival and reduces cancer cells to undetectable levels in high-risk multiple myeloma patients.
What could go wrong: This is a small, early-phase trial (50 people) with no results yet. The combination of drugs may cause significant side effects, and the benefit over standard therapy is not proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.